European Society Of Cardiology Congress Research Articles

Exploring the impact of cardiologists expertise on publication metrics

BackgroundIn the field of academic cardiology, the assessment of an author's scholarly impact and professional progression heavily relies on publications and citations. This study investigates whether specific cardiology expertise correlates with accelerated professional growth. MethodsUsing data from the 2023 European Society of Cardiology congress, 948 faculty attendees with an h-index of 30 or higher were analyzed. Expertises were categorized into six groups, and their association with publications and citations peaks was explored. ResultsInterventional cardiologists exhibited the highest annual publication peak, followed by imaging and electrophysiology experts. However, no significant differences were observed in citation peaks among expertise groups. While imaging experts initially appeared to reach citation peaks faster, this effect diminished after statistical adjustments. Additionally, holding multiple expertise areas prolonged the time to reach publication and citation peaks by approximately six years. ConclusionThis study underscores the influence of expertise in interventional cardiology on publication peaks but suggests that citation peaks and career progression velocity remain unaffected by expertise type. Furthermore, it highlights that holding multiple areas of expertise slowers the attainment of career peak for scholarly authors.

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress.

To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress. The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create "cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)" biomarker and evaluate its association with major CV events regardless of plasma LDL-C levels or age. Safety and efficacy data of inclisiran, a PCSK9-interfering mRNA (PCSK9i) administered subcutaneously twice annually, were presented. Data on two new PCSK9is were presented, recaticimab, an oral drug, and lerodalcibep, a subcutaneous drug with a slightly different architecture than currently available PSCK9is. A phase 1 trial on muvalaplin, an oral lipoprotein (a) inhibitor, was presented. An atherosclerotic CV disease (ASCVD) risk prediction algorithm for the Asian population using SCORE2 data was presented. Long-term follow-up of patients enrolled in the CLEAR outcomes trial showed sustained and more significant ASCVD risk reduction with bempedoic acid in high-risk patients. The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.

2023 European Society of Cardiology (ESC) Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

The 2023 update of the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease (CVD) in patients with diabetes was presented in a symposium session at the ESC Congress 2023, held in Amsterdam, the Netherlands, from the 25th–28th of August. The updates redefined the 2019 guidelines, acknowledging recent findings from cardiovascular outcome trials (CVOT) on the safety and efficacy of glucose-lowering medications to provide practice-changing recommendations. The session also introduced a novel tool in predicting CVD risk, SCORE2-Diabetes, an innovative model that accounts for conventional and diabetes-related risk factors, stratified by geographical location.

ESC Congress 2022 Imaging Highlights.

Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.

Report from the European Society of Cardiology Congress 2022 in Barcelona: new discoveries in cardiovascular pharmacotherapy

The following paper presents an overview of the key studies presented at the European Society of Cardiology Congress 2022. The DELIVER study provided information on the efficacy of dapagliflozin independent of left ventricular ejection fraction. The ADVOR trial confirmed the beneficial effect of the inclusion of acetazolamide as a diuretic in the initial phase of acute decompensated heart failure. The REVIVED study showed no advantage of percutaneous revascularisation over optimal pharmacotherapy in stable coronary artery disease. The SECURE study demonstrated the benefit of the so-called polypill over taking each drug separately. The PANTHER meta-analysis indicated a better effect of using P2Y12 inhibitors over aspirin in chronic therapy. The ALL-HEART study revealed no benefit in treating asymptomatic hyperuricemia in patients with coronary artery disease with allopurinol. The INVICTUS trial demonstrated the superiority of vitamin K antagonists over non-vitamin K antagonist oral anticoagulants in preventing embolic complications in cases where valvular defects of rheumatic origin co-occur with atrial fibrillation.

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny.

It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping.

SECURE, ADVOR and REVIVED: Clinical Trials Presented at ESC 2022.

In this article, three important clinical trials presented at the 2022 European Society of Cardiology Congress have been selected for a brief discussion. These are the SECURE, ADVOR and REVIVED-BCIS2 trials, all of which are investigator-initiated studies whose findings are of interest given their potential to impact clinical practice, ultimately improving current patient care and clinical outcomes.

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 European Society of Cardiology Congress.

Focused review of select studies presented at the 2022 European Society of Cardiology Congress. Included studies assessed the effects of aspirin and omega-3 fatty acid supplements on heart failure (ASCEND study); the impact of icosapent ethyl on ST-elevation MI incidence (REDUCE-IT); air temperature's effect on cardiovascular mortality (EXHAUSTION project); LVEF outcomes after troponin-guided neurohormonal blockade for the prevention of anthracycline toxicity; efficacy of routine stress testing after high-risk PCI (POST-PCI trial); influenza vaccine among patients with acute coronary syndromes (VIP-ACS trial); empagliflozin in patients with acute myocardial infarction (EMMY); effects of comprehensive imaging-based cardiovascular screening on death and cardiovascular events (DANCANVAS); safety of long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE); and use of a cardiovascular polypill as a global strategy to improve secondary prevention (SECURE). Research presented at the 2022 ESC Congress highlighted many novel applications of preventative and treatment strategies in cardiology, including the effects of environmental risk factors on the incidence of cardiovascular disease.

New honour in memory of one of the giants of cardiology goes to Hannover Medical School.

All correspondence relating to this article should be sent tocardiopulse@unicatt.it The 2022 Desmond Julian Award was presented to Thomas Thum MD, PhD, Director of the Institute for Molecular and Translational Therapeutic Strategies (IMTTS), Hanover, Germany at the European Society of Cardiology Congress in August (Figure 1). Prof. Thum and the IMTTS team were awarded the honour for a paper about RNA therapy for cardiovascular disease. This year’s prize—only the second since the award was established—was presented in person at a ceremony attended by the late cardiologist’s widow Claire Julian (Figure 2). The annual prize recognizes one outstanding, original paper published in the EHJ during the previous year. Papers are judged by the Editor-in-Chief and the Executive Editors on originality, methodology, presentation, and importance, also utilizing accepted bibliometric indexes. The Award commends not only the first author of the paper but also the team in which he or she is working.

Did the ‘Digital Experience’ improve women’s representation at the European Society of Cardiology congress?

Did the ‘Digital Experience’ improve women’s representation at the European Society of Cardiology congress?

ESC-Leitlinien 2021 zur Schrittmacher- und Resynchronisationstherapie

The new European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization therapy were presented together with the new ESC heart failure guidelines at the ESC congress in September. The new document includes detailed sections on patient evaluation and clinical assessment, implantation, minimizing complications and patient follow-up. The guidelines have been updated and expanded particularly on the approach to reflex syncope, the indications after transcatheter aortic valve implantation (TAVI) and the perioperative management. The indications for cardiac resynchronization therapy (CRT) are now in line with the simultaneously published ESC heart failure guidelines. New physiological forms of stimulation and leadless pacing are now included in the guidelines.

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress.

This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021.

New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021.

Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress.

As a consequence of the COVID-19 pandemic, the European Society of Cardiology (ESC) was forced to pivot the scientific programme of the ESC Congress 2021 into a totally new format for online consumption, The Digital Experience. A variety of new suppliers were involved, including experts in TV studio, cloud infrastructure, online platforms, video management, and online analytics. An information technology platform able to support hundreds of thousands simultaneous connections was built and cloud computing technologies were put in place to help scale up and down the resources needed for the high number of users at peak times. The video management system was characterized by multiple layers of security and redundancy and offered the same fluidity, albeit at a different resolution, to all user independently of the performance of their internet connection. The event, free for all users, was an undisputed success, both from a scientific/educational as well as from a digital technology perspective. The number of registrations increased by almost four-fold when compared with the 2019 record-breaking edition in Paris, with a greater proportion of younger and female participants as well as of participants from low- and middle-income countries. No major technical failures were encountered. For the first time in history, attendees from all around the globe had the same real-time access to the world’s most popular cardiovascular conference.

Survey on e-health knowledge and usage in general cardiology of the Council of Cardiology Practice and the Digital Health Committee.

The Council for Cardiology Practice of the European Society of Cardiology (ESC), in collaboration with the Digital Health Committee (DHC), undertook an electronic survey with 15 question multiple-choice questionnaire sent to 32 461 members of the ESC with the aim to assess the knowledge and usage of digital health (DH) technologies (DHTs) by office-based cardiologists. Of 559 respondents, 57% graded their knowledge about DH as 'fair' and three quarters identified the correct definition of DH. Clinical information systems, mHealth Apps, and telemedicine were the most frequently used DHTs, but 41% of respondents had concerns about their ethical and data transparency. Lack of legal clarity, low patient motivation, limited DH literacy, and poor access to DH were perceived as the main barriers to the adoption of DH. Seventy percent of the respondents were aware of the DH pages on the ESC website and 76% of the educational sessions in the DH area during the ESC Congress 2019. Only 16% had not read articles on DH. Eight-eight percent of responders declared that they would 'probably' or definitely attend future educational initiatives on DHT.

Highlights from European Society of Cardiology Congress: a focus on nutrition

The relationship between nutrition and cardiovascular health has emerged over the past two decades. European Society of Cardiology has become a leading platform for discussion. This article encompasses the main findings of a multitude of studies presented at ESC. The assessment of population dietary patterns should include the data on the profile of food and nutrients as well as their lifestyle, socio-economic status, the quality of products, and macronutrients replacement. The study design aimed at assessing dietary patterns nutrition should be a prospective long-term study focusing on collecting the data on ethnic and socio-economic components as well as the data suggesting the adherence to a particular dietary pattern.

‘Digoxin conundrum – Time for validation?’

Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association

Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well

Purpose of ReviewThe review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the 2020 European Society of Cardiology (ESC) Congress—The Digital Experience.Recent FindingsThe studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction. In addition, we review the BPLTTC analysis on blood pressure treatment across blood pressure levels and CVD status and discuss findings from the BRACE CORONA study that examined continuing versus suspending angiotensin-converting enzyme inhibitor or angiotensin receptor blockers in patients on these antihypertensive medications who were hospitalized with COVID-19 infection.SummaryThe studies presented at the 2020 digital ESC Congress highlight the continuing advancements in the field of CVD prevention.

Latest news on heart failure and atrial fibrillation from the European Society Of Cardiology Congress 2020.

Latest news on heart failure and atrial fibrillation from the European Society Of Cardiology Congress 2020.